Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study

Infection
Mohammed J Al-JaghbeerMajdi N Al-Hasan

Abstract

This case-case-control study aims to identify clinical predictors for pneumonia due to Pseudomonas aeruginosa (PA) which is (1) susceptible to all routinely tested antipseudomonal beta-lactams (APBL-S) and (2) resistant to at least one antipseudomonal beta-lactam (APBL-R). Hospitalized adults with acute bacterial pneumonia at Palmetto Health hospitals in Columbia, SC, USA from January 1, 2012 to April 15, 2014 were identified. Multivariate logistic regression was used to determine risk factors for pneumonia due to APBL-S PA and APBL-R PA. Among 326 unique patients, 119 had pneumonia due to APBL-S PA (cases), 44 due to APBL-R PA (cases) and 163 due to ceftriaxone-susceptible bacteria (controls). Bronchiectasis [odds ratio (OR) 5.7, 95% confidence intervals (CI) 1.3-39.2], interstitial lung disease (OR 6.2, 95% CI 1.5-42.6), prior airway colonization with APBL-S PA (OR 7.2, 95% CI 1.1-139.4) and recent exposure to both antipseudomonal beta-lactam (APBL; OR 2.2, 95% CI 1.1-4.5) and nonpseudomonal beta-lactams (OR 2.6, 95% CI 1.0-6.8) were independently associated with increased risk of APBL-S PA pneumonia. Bronchiectasis (OR 8.3, 95% CI 1.7-46.6), prior airway colonization with APBL-R PA (OR 14.9, 95% CI 2.0-312.9) and recent use ...Continue Reading

References

Aug 3, 1999·American Journal of Respiratory and Critical Care Medicine·M RuizA Torres
Feb 6, 2002·Journal of Thoracic Imaging·Rosita M ShahPaul W Spirn
May 3, 2002·The New England Journal of Medicine·Alan F Barker
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisabeth ParamythiotouAntoine Andremont
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Valerie AloushYehuda Carmeli
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Jun 15, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·David J WeberMichael S Niederman
Aug 12, 2008·The American Journal of Medicine·Hae Suk CheongKyong Ran Peck
Feb 5, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vered SchechnerYehuda Carmeli
Dec 3, 2009·JAMA : the Journal of the American Medical Association·Jean-Louis VincentUNKNOWN EPIC II Group of Investigators
Dec 25, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M MonteroH Knobel
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
Dec 4, 2012·The Journal of Hospital Infection·A NakamuraA Ohsaka
Oct 23, 2013·Intensive Care Medicine·Jordi RelloThiago Lisboa
Feb 7, 2014·The New England Journal of Medicine·Richard G Wunderink, Grant W Waterer
May 6, 2015·Critical Care : the Official Journal of the Critical Care Forum·Nazaret Cobos-TriguerosJosé Antonio Martínez
Jul 23, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ritu BanerjeeRobin Patel
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Sep 23, 2016·JAMA Internal Medicine·James BaggsJohn A Jernigan
Nov 5, 2016·Diagnostic Microbiology and Infectious Disease·Katie Lynn HammerMajdi N Al-Hasan

❮ Previous
Next ❯

Citations

Aug 28, 2019·Antibiotics·Majdi N Al-HasanJulie Ann Justo
Mar 10, 2019·Critical Care : the Official Journal of the Critical Care Forum·Catia CillónizAntoni Torres
Jul 11, 2019·The New England Journal of Medicine·Allan S Brett, Majdi N Al-Hasan
Sep 16, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marion ElligsenNick Daneman
Feb 11, 2021·Pharmacy : Journal of Pharmacy, Education and Practice·Stephanie ShealyMajdi N Al-Hasan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.